The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
If ACTIV 2 Phase 3 patients are also taking dexamethasone in all patient cohorts then how could the trial result be any different? If there is a belief that steroids will not be administered then where has this been stated?
I wasn't ramping them I was alerting fellow Beowulf investors to take a look. The top line Phase 3 results released this morning are very disappointing. Nevertheless there has been a 35% reduction in deaths compared to placebo (7 deaths cf 12) , but the relatively small trial size (630) deems it not statistically significant. It was looking like a fantastic opportunity as the company despite only having around 15 staff was advertising senior posts in USA and EU. I've lost a fortune. Their rns is worth reading as a lesson for what can go wrong.
I must have missed it then because I've just checked the framed montage I've got on my lounge wall which I thought had exclusively every single one of pmjh's comments and associated links. I can't be the only one trying to create their own Banksy equivalent so can someone else check theirs. Ta
Gambier
The opportunity I am referring to is to buy here when the share price is much lower than in Sweden. Or sell here when the share price is higher here than in Sweden (rare but happened a couple of weeks ago). If the gap is large (eg 15%) you can be sure it will close up eventually. The gap has been as big as 25%. I will be waiting for the buyout offer because that is the only time that shareholders in both countries will get exactly the same price (the exchange rate mid price). I will never sell when the price here is significantly less than Sweden. If it is higher than Sweden then that will be another opportunistic selling opportunity. When the YES comes these misalignments could become big again.
Gambier
The share price in Sweden has fallen 3%. That is trivial. If it was true that the Minister said he would make a decision in the second week of February (Greentea never provided proof of this) and now the Minister has given Beowulf until 14 Feb to respond, then a fall of 3% is to be expected. The Swedish market is very efficient. The volume today is 25 times higher and the spread is less than 1%. Here it is currently 4%. To gauge sentiment follow the Swedish market. The UK market is there for exploiting the differential, if one is bold enough.
Matml74
Are you inferring that the delay in releasing results might be because Synairgen is awaiting data on the secondary endpoints, which if so, means that trial must have satisfied the primary endpoints?
This is my understanding of what I think you are saying. Am I correct?
Dear Greentea1
Please could you upload the text which states that KPT will give a message after the first week of February. That statement makes it is the closest we've been to a YES in ten years. I want to print it off and frame it.
https://www.reuters.com/markets/currencies/
I am finding it to be 12.52 SEK = £1 at reuters.
I love the way the share price lags on this trivial volume AIM market. It gave me a lot of confidence to buy heavily when the gap was 20%.
Changing the subject to my pet obsession. I'd like to invite you to check out the newly upgraded Synairgen.com website and ask yourself why would a small UK biotech company with around 30 employees be posting adverts for 5 senior positions based in the USA. I will explain. It is because they are just about to be awarded Emergency Use Authorisation in the USA for their inhaled interferon beta treatment for Covid 19.
This new trail involves asking the 25 patients every single day. That wasn't the case in the original trial. It sounds like they are seeking more accuracy as to when the long covid symptoms actually diminish to zero. This might infer that a large number of the trialist that actually got the drug (not the placebo) and whom were asked questions at day 90 do not have long covid anymore .